Global Cancer related Pain Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Global Cancer related Pain Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • August 2019 •
  • 125 pages •
  • Report ID: 5811363 •
  • Format: PDF
High levels of pipeline activity are being observed in Cancer related Pain treatment during 2019. Clinical development activities are being undertaken by more than 30 companies including Alexza Pharmaceuticals Inc, AngioChem Inc, Aoxing Pharmaceutical Company Inc, Aphios Corp, Aquilus Pharmaceuticals Inc and others.

A Significant contribution to the Cancer related Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Cancer related Pain pipeline included 32 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Cancer related Pain condition and increased access to investments is encouraging growth of Cancer related Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Cancer related Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Cancer related Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Cancer related Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Cancer related Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Cancer related Pain pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Cancer related Pain pipeline and formulate effective research and development strategies.

Research Methodology
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Cancer related Pain Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Cancer related Pain drugs
- Late phase: Phase 3 and in-approval Cancer related Pain drugs

Companies involved in the Pipeline-
- Company overview
- Snapshot
- Cancer related Pain therapeutic treatment activities

Details for each Cancer related Pain drug candidate-
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details

Other details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate

Recent Cancer related Pain therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news